Amgen, Sandoz Both Winners And Losers At Federal Circuit
The Court of Appeals for the Federal Circuit on July 21 rendered its decision on the applicability and interpretation of two key provisions of the Biologics Price Competition and Innovation Act....To view the full article, register now.
Already a subscriber? Click here to view full article